Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804057 · ClinicalTrials.gov registry record
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
A clinical trial of Systemic Lupus Erythematosus, sponsored by CorEvitas.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06804057: Recruiting study of Systemic Lupus Erythematosus, sponsored by CorEvitas.
NCT06804057 is a study of Systemic Lupus Erythematosus that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 1,000 participants, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06804057, a study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.
Primary Outcome
The major clinical outcome include an assessment of the epidemiology of Systemic Lupus Erythematosus; to better understand the presentation and natural history.
Conditions Studied
Interventions
- OTHER Blood Collection
Study Locations (1)
Massachusetts
- CorEvitas - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-09-26 |
| Est. Completion | 2099-12-31 |
What NCT06804057 shows while recruiting
NCT06804057 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Blood Collection is the first listed.
NCT06804057 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06804057 about?
NCT06804057 is a clinical study titled "CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry". Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.
What is the current status of trial NCT06804057?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-09-26. Estimated completion is 2099-12-31.
What conditions does trial NCT06804057 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT06804057?
The interventions under investigation include: Blood Collection (OTHER).
Who is sponsoring clinical trial NCT06804057?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804057 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06804057's enrollment target sits among peer trials
1,000 6th of 99 higher than 91 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RECRUITING
-
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI